{
    "nct_id": "NCT06526793",
    "official_title": "A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)",
    "inclusion_criteria": "* Aged 18 to 80 years old\n   * Histologically confirmed relapsed refractory FL (Module 1) and DLBCL (Module 2) after at least 2 prior lines of therapy\n   * ECOG performance status 0 to 2\n   * Locally confirmed CD-19 expression in lymphoma cells after progression from last CD 19 directed therapy\n   * FDG-avid disease with at least one bi-dimensionally measurable nodal lesion (defined as > 1.5 cm in its longest dimension), or extranodal lesion (defined as > 1.0 cm in its longest dimension)\n   * Adequate hematological function: ANC ≥ 1000/mm3, platelets\n\n     * 75,000/mm3, hemoglobin ≥ 9 g/dL. Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening\n   * Adequate liver function: total bilirubin <1.5x ULN, AST/ALT ≤ 3xULN Note: Patients with documented history of Gilbert's Syndrome and in whom total bilirubin elevations are accompanied by elevated indirect bilirubin are eligible)\n   * Adequate renal function: creatinine clearance (CrCl) of ≥ 45 mL/min\n\n   The above is a summary, other inclusion criteria details may apply.\n2. Key\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Diagnosis of CLL, Burkitt lymphoma, or Richter's transformation\n   * Active CNS involvement by B-NHL\n   * Leukemic presentation of B-NHL\n   * History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis\n   * Prior therapy with T-cell engager (TCE) within 8 weeks, CAR T- cell therapy or autologous Hematopoietic Stem Cell Transplantation (HSCT) within 12 weeks, or prior allogeneic HSCT within 24 weeks of first dose of AZD0486\n   * Requires chronic immunosuppressive therapy\n   * Unresolved non hematological AEs ≥ Grade 2 from prior therapies; history of ≥ Grade 3 CRS or neurotoxicity from prior CAR-T or TCE therapy\n   * History of major cardiac abnormalities.\n   * If female, participant must not be pregnant or breastfeeding.\n\nThe above is a summary, other exclusion criteria details may apply.",
    "miscellaneous_criteria": "1. Key"
}